Abstract
Emergency department visits for atrial fibrillation (AF) have increased in the last decade. The efficacy and safety of vernakalant hydrochloride injection, a novel, relatively atrial-selective multiple ion channel blocker, in converting AF to sinus rhythm (SR), were recently reported. A pooled post hoc analysis of patients with recent-onset AF from 2 multicenter, placebo (PBO)-controlled Atrial arrhythmia Conversion Trials (ACT I and ACT III) assessed the efficacy of vernakalant in achieving SR based on patients' medical history and other baseline characteristics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
